Results 111 to 120 of about 3,377,180 (268)

Effects of three different diets on glucose, insulin, triglycerides and glucose-dependent insulinotropic-polypeptide (GIP).

, 2013
Effects of a low-fat diet (open circles, regular lines), low-carbohydrate diet (open squares, dashed lines) and a Mediterranean-type diet (open triangles, dotted lines) with similar total energy intake as the low-fat and low-carbohydrate diets contained ...
Bekim Bunjaku (490259), Christine Jaredsson (490258), Hanna Fernemark (490257), Ulf Rosenqvist (490260), Fredrik H. Nystrom (490261), Hans Guldbrand (490262)   +5 more
core   +1 more source

Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials and Methods Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials.
Giacomo Ruotolo, Charles Harris, Yanzhu Lin, Jonathan M. Wilson, Valentina Pirro, Kevin L. Duffin, Melissa K. Thomas, Mark L. Hartman, Ciara O' Neill, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Naveed Sattar, Stephen J. Nicholls   +13 more
wiley   +1 more source

Effect of phenylbutazone administration on the enteroinsular axis in horses with insulin dysregulation

Journal of Veterinary Internal Medicine
Background Phenylbutazone is prescribed for laminitis‐associated pain and decreases glucose and insulin responses to an oral glucose test (OGT) in horses with insulin dysregulation (ID).
Kate L. Kemp, Jazmine E. Skinner, François‐René Bertin   +2 more
doaj   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties

, 2009
International audienceC-terminal acylation of Lys with myristic (MYR; tetradecanoic acid), palmitic (PAL; hexadecanoic acid) and stearic (octadecanoic acid) fatty acids with or without N-terminal acetylation was employed to develop long-acting analogues ...
Clifford J. Bailey, Kerr, Barry D., Irwin, Nigel, Barry D. Kerr, Flatt, Peter R., Gault, Victor A., Nigel Irwin, Peter R. Flatt, Victor A. Gault, Bailey, Clifford J., Finbarr P.M. O’Harte, O'Harte, Finbarr P.M.   +11 more
core   +1 more source

Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Compare healthcare cost trends among older adults with obesity or overweight treated with tirzepatide versus no treatment. Materials and Methods Retrospective cohort study using real‐world data from US Komodo Research Dataset, 8 November 2022 to 30 September 2025.
Navneet Upadhyay, Ali Bonakdar, Keshab Subedi, Soutrik Banerjee, Benjamin Behrend, Emily R. Hankosky   +5 more
wiley   +1 more source

Out of stock: A brief clinical reference for rough equivalency of glucagon‐like peptide‐1 (GLP‐1) ± glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes

Journal of Diabetes
Highlights Despite the common practice of switching patients from one medicine to another—to improve efficacy, safety, or tolerability—guidance on how to do so is uncommon.
Leigh Perreault, Bryan C. Bergman
doaj   +1 more source

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj, Marvin Fischer, Michael B. Davidson, Abdul M. Tarafder, Christopher J. Michaels, Rachel H. Tao, Alex Pashley, Jess Amis, Josefine Redig   +8 more
wiley   +1 more source

Additive Glucagonotropic and Insulinotropic Effects of Glucose‐Dependent Insulinotropic Polypeptide and Alanine in Fasted Healthy Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims/Hypothesis Glucose‐dependent insulinotropic polypeptide (GIP) is a bidirectional glucose‐stabilising hormone potentiating insulin secretion at high glucose levels and glucagon secretion during normal‐to‐low plasma glucose levels. Preclinically, GIP and the amino acid alanine show synergistic glucagonotropic effects at low glucose levels ...
Julie Warnøe, Aliya M. Thomas, David S. Mathiesen, Mathilde K. Preskou, Joachim Størling, Mikkel B. Christensen, Bolette Hartmann, Jens J. Holst, Samuel A. J. Trammell, Jonathan E. Campbell, Thomas F. Dejgaard, Asger B. Lund, Filip K. Knop, Lærke S. Gasbjerg   +13 more
wiley   +1 more source

Recent clinical and pharmacological advancements of incretin-based therapy and the effects of incretin on physiology

Journal of Diabetology
A novel therapeutic target for diabetes mellitus is incretin-based therapies, glucagon-like peptide-1, and glucose-dependent insulinotropic polypeptides are released from the gastrointestinal (GI) tract and act on beta cells of pancreatic islets by ...
Bhaskar Pal, Moitreyee Chattopadhyay
doaj   +1 more source